Announcements
- Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
- Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives
- Communiqué à la requête de la FSMA sur les transactions avec QliniQ
- Communication at the request of the FSMA on the transactions with Qliniq
- Hyloris to Report 2023 Full-Year Results on 14 March 2024
- Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024
- Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au Canada
- Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada
- Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
- Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions Dentaires
More ▼
Key statistics
On Saturday, Hyloris Pharmaceuticals SA (0AB6:LSE) closed at 0.00, -100.00% above its 52-week low of 11.09, set on Dec 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 11.70 |
Average volume | -- |
---|---|
Shares outstanding | 28.00m |
Free float | 12.15m |
P/E (TTM) | -- |
Market cap | 327.60m EUR |
EPS (TTM) | -0.5795 EUR |
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼